BSECompany Update16h ago · 14 Oct 2026, 08:20 pm
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Dr Reddys Laboratories Ltd · 500124
✦ AI SummaryRegulatory
Dr Reddys Laboratories Ltd has informed that the USFDA completed a Pre-Approval Inspection (PAI) at its FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, with three observations issued in a Form 483, which will be addressed within the stipulated timeline.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk1/10
Liquidity Impact6/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Attachments (1)
📄pdf
Download →
98134afb-3187-4e66-9565-30cf87288816.pdf
View document text
Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills
Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900
Fax: + 91 40 4900 2999
Email: mail@drreddys.com
Web: www.drreddys.com
October 14, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015
This is to inform you that the United States Food and Drug Administration (USFDA) completed a Pre-
Approval Inspection (PAI) at our FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh. The
inspection was conducted from October 8, 2026, to October 9, 2026. We have been issued a Form 483
with three observations, which we will address within the stipulated timeline.
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR